Shares of Oncothyreon (ONTY) fall 32.4% in premarket trading after Merck KgaA (MKGAF.PK)...

|By:, SA News Editor

Shares of Oncothyreon (ONTY) fall 32.4% in premarket trading after Merck KgaA (MKGAF.PK) announces that studies on the experimental lung-cancer drug Stimuvax won't be completed until next year. Stimuvax is being developed by Merck KGaA under a license agreement with Oncothyreon.